News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
The facility will be positioned as a Centre of Excellence for tertiary care services
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Subscribe To Our Newsletter & Stay Updated
